Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Assess the Long Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04530344
Recruitment Status : Recruiting
First Posted : August 28, 2020
Last Update Posted : November 12, 2020
Sponsor:
Information provided by (Responsible Party):
Incyte Corporation

Brief Summary:
The purpose of this study is to evaluate the duration of response following withdrawal of ruxolitinib cream (Cohort A vehicle group), safety and maintenance of response with continued use of ruxolitinib cream in participants who have completed either Study NCT04052425 or NCT04057573 (parent studies) in which the participants will have been using ruxolitinib cream BID for the previous 28 to 52 weeks depending on their initial randomization in the parent study.

Condition or disease Intervention/treatment Phase
Vitiligo Drug: ruxolitinib Drug: Vehicle Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 500 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Masking Description: Double Blind
Primary Purpose: Treatment
Official Title: A Double-Blind, Vehicle-Controlled, Randomized Withdrawal and Treatment Extension Study to Assess the Long-Term Efficacy and Safety of Ruxolitinib Cream in Participants With Vitiligo
Actual Study Start Date : September 24, 2020
Estimated Primary Completion Date : January 18, 2024
Estimated Study Completion Date : January 18, 2024

Resource links provided by the National Library of Medicine

MedlinePlus Genetics related topics: Vitiligo
MedlinePlus related topics: Vitiligo

Arm Intervention/treatment
Experimental: Cohort A : ruxolitinib cream
Participants who achieve complete or almost complete facial repigmentation (achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to ruxolitinib cream or vehicle.
Drug: ruxolitinib
ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
Other Name: INCB018424 Cream

Placebo Comparator: Cohort A : Vehicle
Participants who achieve complete or almost complete facial repigmentation (ie, achieve ≥ F VASI90) at Week 52 in the parent study will be assigned to Cohort A and will be randomized 1:1 to vehicle cream
Drug: Vehicle
Vehicle cream is a topical formulation applied as a thin film to affected areas.

Experimental: Cohort B : roxolitinib cream
Participants who did not achieve ≥ F-VASI90 at Week 52 of the parent studies will be assigned to Cohort B and will continue ruxolitinib cream
Drug: ruxolitinib
ruxolitinib cream is a topical formulation applied as a thin film to affected areas BID.
Other Name: INCB018424 Cream




Primary Outcome Measures :
  1. Cohort A : Time to Relapse [ Time Frame: Extension period through Week 108 ]
    Defined as the time when a participant does not achieve F-VASI75. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study


Secondary Outcome Measures :
  1. Cohort A : Time to maintain ≥ F-VASI90 response [ Time Frame: Extension period through Week 108 ]
    Defined as time to maintain ≥ 90% improvement in F-VASI Score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study

  2. Proportion of participants achieving F-VASI50 [ Time Frame: Extension period through Week 108 ]
    ≥ 50% improvement from baseline in F-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.

  3. Proportion of participants achieving F-VASI75 [ Time Frame: Extension period through Week 108 ]
    ≥ 75% improvement from baseline in F-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.

  4. Proportion of participants achieving F-VASI90 [ Time Frame: Extension period through Week 108 ]
    ≥ 90% improvement from baseline in F-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.

  5. Proportion of participants achieving T-VASI50 [ Time Frame: Extension period through Week 108 ]
    ≥ 50% improvement from baseline in T-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.

  6. Proportion of participants achieving T-VASI75 [ Time Frame: Extension period through Week 108 ]
    ≥ 75% improvement from baseline in T-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.

  7. Proportion of participants achieving T-VASI90 [ Time Frame: Extension period through Week 108 ]
    ≥ 90% improvement from baseline in T-VASI score. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.

  8. Actual Measurement of F-VASI [ Time Frame: Baseline through Week 108 ]
    F-VASI actual measurement from parent studies NCT04052425 or NCT04057573 will be utilized for baseline data

  9. Change in F-VASI [ Time Frame: Baseline through Week 108 ]
    Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure change in F-VASI

  10. Percentage Change in F-VASI [ Time Frame: Baseline through Week 108 ]
    Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure percent change in F-VASI

  11. Actual Measurement of T-VASI [ Time Frame: Baseline through Week 108 ]
    T-VASI actual measurement from parent studies NCT04052425 or NCT04057573 will be utilized for baseline data

  12. Change in T-VASI [ Time Frame: Baseline through Week 108 ]
    Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure change in T-VASI

  13. Percentage Change in T-VASI [ Time Frame: Baseline through Week 108 ]
    Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure percent change in T-VASI

  14. Actual Measurement of T-BSA [ Time Frame: Baseline through Week 108 ]
    T-BSA actual measurement from parent studies NCT04052425 or NCT04057573 will be utilized for baseline data

  15. Change in T-BSA [ Time Frame: Baseline through Week 108 ]
    Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure change in T-BSA

  16. Percentage Change in T-BSA [ Time Frame: Baseline through Week 108 ]
    Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure percent change in T-BSA

  17. Actual Measurement of F-BSA [ Time Frame: Baseline through Week 108 ]
    F-BSA actual measurement from parent studies NCT04052425 or NCT04057573 will be utilized for baseline data

  18. Change in F-BSA [ Time Frame: Baseline through Week 108 ]
    Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure change in F-BSA

  19. Percentage Change in F-BSA [ Time Frame: Baseline through Week 108 ]
    Baseline data from parent studies NCT04052425 or NCT04057573 will be utilized to measure percent change in F-BSA

  20. Proportion of participants achieving a VNS of 4 or 5 [ Time Frame: Extension period through Week 108 ]
    The VNS is a patient-reported measure of vitiligo treatment success, which has a 5-point scale, with 1 being more noticeable and 5 being no longer noticeable. Participants who completed parent studies NCT04052425 and NCT04057573 will begin extension period at week 52 in this study.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Currently enrolled and receiving treatment in INCB 18424-306 (NCT04052425) or INCB 18424-307 (NCT04057573) studies evaluating ruxolitinib cream in participants with vitiligo.
  • Currently tolerating ruxolitinib cream in the parent study and no safety concerns per investigators judgment.
  • Has demonstrated compliance, as assessed by the investigator, with the parent study protocol requirements.
  • Willingness and ability to comply with scheduled visits, treatment plans, and any other study procedures indicated in this protocol.
  • Male and female participants must be willing to take appropriate contraceptive measures to avoid pregnancy or fathering a child.
  • Ability to comprehend and willingness to sign an ICF or written informed consent of the parent(s) or legal guardian and written assent from the participant when possible.

Exclusion Criteria:

  • Has been permanently discontinued from study treatment in the parent study for any reason.
  • Participants with an uncontrolled intercurrent illness or any concurrent condition that, in the investigator's opinion, would jeopardize the safety of the participant or compliance with the Protocol.
  • Pregnant or breastfeeding woman.
  • Participants who live with anyone participating in any current Incyte-sponsored ruxolitinib cream study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04530344


Contacts
Layout table for location contacts
Contact: Incyte Corporation Call Center (US) 1.855.463.3463 medinfo@incyte.com
Contact: Incyte Corporation Call Center (ex-US) +800 00027423 eumedinfo@incyte.com

Locations
Layout table for location information
United States, Arizona
Desert Sky Dermatology Recruiting
Gilbert, Arizona, United States, 85295
United States, California
Center For Dermatology Cosmetic and Laser Surgery Recruiting
Fremont, California, United States, 94538
Marvel Clinical Research Llc Recruiting
Huntington Beach, California, United States, 92647
United States, Florida
San Marcus Research Clinic Inc. Recruiting
Miami Lakes, Florida, United States, 33014
Advanced Pharma Cr Recruiting
Miami, Florida, United States, 33147
Olympian Clinical Research Recruiting
Tampa, Florida, United States, 33614
Forcare Clinical Research Fcr Forward Clinical Trials, Inc Recruiting
Tampa, Florida, United States, 33624
United States, Louisiana
Delricht Clinical Research - Clinedge - Ppds Baton Rouge Recruiting
Baton Rouge, Louisiana, United States, 70809
United States, Massachusetts
Metro Boston Clinical Partners Recruiting
Brighton, Massachusetts, United States, 02135
United States, North Carolina
Wake Research Associates Llc Recruiting
Raleigh, North Carolina, United States, 27612
United States, Tennessee
International Clinical Research Tennessee Llc Recruiting
Murfreesboro, Tennessee, United States, 37130
United States, Washington
Dermatology Specialists of Spokane Recruiting
Spokane, Washington, United States, 99202
Sponsors and Collaborators
Incyte Corporation
Layout table for additonal information
Responsible Party: Incyte Corporation
ClinicalTrials.gov Identifier: NCT04530344    
Other Study ID Numbers: INCB 18424-308
First Posted: August 28, 2020    Key Record Dates
Last Update Posted: November 12, 2020
Last Verified: November 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.

The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
Access Criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
URL: https://www.incyte.com/our-company/compliance-and-transparency

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Incyte Corporation:
INCB018424
Additional relevant MeSH terms:
Layout table for MeSH terms
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases